Salvage radical prostatectomy following focal therapy: functional and oncological outcomes.
Jaime O Herrera-CaceresGregory J NasonNoelia Salgado-SanmamedHanan GoldbergDixon T S WoonThenappen ChandrasekarKhaled AjibGuan Hee TanOmar AlhunaidiTheodorus van der KwastAntonio FinelliAlexandre R ZlottaRobert J HamiltonAlejandro BerlinNathan PerlisNeil E FleshnerPublished in: BJU international (2020)
sRP should be considered as an option for patients who have persistent clinically significant prostate cancer or recurrence after FT. PSMs should be recognised as a risk for recurrent disease after sRP.